{"product_id":"qure-vrio-analysis","title":"uniQure N.V. (QURE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to uniQure N.V. (QURE)'s competitive edge starts here! This VRIO analysis distills exactly how their current resources measure up on the crucial dimensions of Value, Rarity, Inimitability, and Organization. Discover the core strengths - or potential weaknesses - that define their market position and prepare to see the full, game-changing breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 1: Proprietary AAV Gene Therapy Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine that drives uniQure N.V.’s entire future - the Adeno-Associated Virus (AAV) gene therapy platform. This isn't just academic; it’s the technology that produced the recent breakthrough data for AMT-130.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Engine for Pipeline Assets\u003c\/h3\u003e\n\u003cp\u003eThe platform is highly valuable because it’s the engine allowing uniQure to create multiple drug candidates, like AMT-130 for Huntington’s disease (HD) and AMT-260 for epilepsy. The platform’s success is evidenced by the pivotal data for AMT-130, which showed a statistically significant 75% slowing of disease progression at 36 months compared to an external control. Also, the platform’s manufacturing process, which uses insect cells and baculoviruses, is a key component of its value proposition.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on investment: R\u0026amp;D expenses for the three months ending September 30, 2025, were $34.4 million, showing the ongoing commitment to developing assets from this core technology.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Specific Vector Design and Delivery\u003c\/h3\u003e\n\u003cp\u003eWhile the general use of AAV vectors is common in the gene therapy space - uniQure has one approved AAV therapy, Glybera, and co-developed another, Hemgenix - the specific vector designs and CNS delivery methods uniQure has refined over two decades are rare. The proprietary miQURE™ silencing technology, which tailors an artificial micro-RNA to silence the huntingtin gene in AMT-130, is a specific, rare combination of components.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides: The general AAV field is crowded, but the specific, validated CNS delivery systems are less common.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Cost and Time Barrier\u003c\/h3\u003e\n\u003cp\u003eBuilding a comparable, validated platform that has successfully navigated regulatory discussions and produced pivotal data like the 75% slowing in HD progression is incredibly difficult to copy quickly. Direct imitation requires replicating over two decades of manufacturing expertise and clinical validation across multiple indications. The regulatory alignment achieved with the FDA on the statistical analysis plan and CMC requirements for AMT-130 is also a hard-to-replicate institutional asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBuilding a similar platform takes a decade.\u003c\/li\u003e\n\u003cli\u003eMassive R\u0026amp;D spend is required.\u003c\/li\u003e\n\u003cli\u003eClinical validation is a major hurdle.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization: Deployment Across Pipeline\u003c\/h3\u003e\n\u003cp\u003euniQure is clearly organized to deploy this platform across several indications, which is necessary to maximize the return on the core technology investment. The company is actively advancing AMT-130 (HD), AMT-260 (epilepsy, showing a 92% seizure reduction in a case study), and AMT-191 (Fabry disease). The company’s strong liquidity, with $694.2 million in cash as of September 30, 2025, shows they are organized to fund this multi-asset strategy into the future.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Potential\u003c\/h3\u003e\n\u003cp\u003eThe core technology itself represents a \u003cstrong\u003esustained competitive advantage\u003c\/strong\u003e, provided the pipeline continues to deliver commercially viable assets. The platform’s modularity allows for the rapid development of new candidates by changing only the disease-specific gene cassette. This foundational technology, supported by a strong balance sheet, gives uniQure a long-term moat in its chosen CNS and liver-directed disorder areas. If AMT-130 gains approval, it validates the entire platform’s approach. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data\/Example\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEngine for AMT-130 (\u003cstrong\u003e75%\u003c\/strong\u003e disease slowing) and AMT-260.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eProprietary miQURE™ technology and two decades of AAV expertise.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires replicating years of R\u0026amp;D and clinical validation milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eActively deploying across HD, MTLE, and Fabry pipelines; $694.2 million cash position as of Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eCore technology moat, contingent on successful commercialization of pipeline assets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 2: AMT-130 Huntington's Disease Clinical Data Package\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the only current evidence of disease modification for HD, with 36-month data showing a statistically significant 75% slowing in progression on the cUHDRS endpoint.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This specific, long-term dataset for a devastating neurological disease is unique in the market right now. The data is based on 29 patients treated with AMT-130, with 12 patients in the high-dose group reaching 36 months of follow-up.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors can run trials, but they cannot replicate uniQure’s existing three-year data set. The therapy is a direct, single-dose infusion into the caudate and striatum regions of the brain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Mixed. The organization was organized to file based on this data, with a planned BLA submission in the first quarter of 2026. However, the recent FDA feedback shows a disconnect in interpretation, as final meeting minutes confirm the agency believes the Phase I\/II data are unlikely to provide the primary evidence to support a BLA submission. The company plans to urgently request a follow-up meeting with the FDA in the first quarter of 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The data is powerful, but the regulatory uncertainty means its value is currently capped until the path forward is clear. The stock price surged nearly 250% following the September data readout, but fell close to 11% after the November FDA feedback. The company reported cash, cash equivalents and current investment securities of approximately $377.0 million as of June 30, 2025, and $0.69 Billion USD as of September 2025. Total assets were $888.38M for Q4 2025, with a market cap of $1.29 billion.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEndpoint Measure\u003c\/th\u003e\n\u003cth\u003eSlowing at 36 Months (High-Dose AMT-130 vs. External Control)\u003c\/th\u003e\n\u003cth\u003eStatistical Significance (p-value)\u003c\/th\u003e\n\u003cth\u003eMean Change from Baseline (Treated)\u003c\/th\u003e\n\u003cth\u003eMean Change from Baseline (Control)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposite Unified Huntington's Disease Rating Scale (cUHDRS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.003\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-0.38\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-1.52\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Functional Capacity (TFC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.033\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymbol Digit Modalities Test (SDMT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0.057\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStroop Word Reading Test (SWRT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e113%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.002\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Motor Score (TMS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0.174\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eMean cerebrospinal fluid (CSF) neurofilament light chain (NfL) showed a mean reduction of \u003cstrong\u003e8.2%\u003c\/strong\u003e compared with controls, with levels remaining below baseline at 36 months.\u003c\/li\u003e\n\u003cli\u003eThe analysis included n=17 patients in the high-dose group and n=940 in the propensity score-weighted external control for cUHDRS.\u003c\/li\u003e\n\u003cli\u003eAMT-130 has been granted breakthrough therapy designation and regenerative medicine advanced therapy (RMAT) designation from the FDA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 3: Extended Financial Runway and Liquidity\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides operational flexibility and shields the company from immediate, dilutive financing needs, which is crucial given the regulatory setback.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs struggle here, but uniQure’s recent capital raise gives them a strong position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can raise capital, but uniQure’s current balance sheet is a specific, achieved state.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Excellent. Management executed a major financing in September 2025, raising net proceeds of approximately \u003cstrong\u003e$323.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (for now). As of September 30, 2025, cash of \u003cstrong\u003e$694.2 million\u003c\/strong\u003e is expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e. That’s a huge buffer.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the extended runway:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from September 2025 Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$323.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Investment Securities (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$694.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Investment Securities (as of 12\/31\/2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$367.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Operational Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExisting Debt Refinanced Maturity Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 2030\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional liquidity and debt structure details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe September 2025 financing included an upsized underwritten public offering raising net proceeds of approximately \u003cstrong\u003e$323.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net increase in cash from December 31, 2024, to September 30, 2025, was primarily attributable to proceeds of \u003cstrong\u003e$404.2 million\u003c\/strong\u003e raised through public offerings of ordinary shares and pre-funded warrants.\u003c\/li\u003e\n\u003cli\u003eThe Company also announced the refinancing of its existing \u003cstrong\u003e$50 million\u003c\/strong\u003e debt outstanding to extend the term to \u003cstrong\u003eOctober 2030\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAn additional term loan tranche of \u003cstrong\u003e$100 million\u003c\/strong\u003e could be drawn upon achieving a pre-defined regulatory milestone for AMT-130.\u003c\/li\u003e\n\u003cli\u003eA third tranche of \u003cstrong\u003e$25 million\u003c\/strong\u003e is available subject to the lender's approval.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ending September 30, 2025, was \u003cstrong\u003e$80.5 million\u003c\/strong\u003e, or \u003cstrong\u003e$1.38\u003c\/strong\u003e basic and diluted loss per ordinary share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 4: Strategic Contract Manufacturing Agreement with Genezen\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCore Capability 4: Strategic Contract Manufacturing Agreement with Genezen\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eExpected reduction in annual cash burn by approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e. Total consideration received was \u003cstrong\u003e$25 million\u003c\/strong\u003e, comprised of \u003cstrong\u003e$12.5 million\u003c\/strong\u003e in Series C Preferred Stock and a \u003cstrong\u003e$12.5 million\u003c\/strong\u003e convertible note. The transaction facilitates the planned repayment of \u003cstrong\u003e$50 million\u003c\/strong\u003e of outstanding debt.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction Component\u003c\/th\u003e\n\u003cth\u003eFinancial Amount\/Term\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Consideration Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Annual Cash Burn Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Repayment Planned\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreferred Stock Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConvertible Note Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Outsourcing manufacturing while retaining preferential access is a smart, though not entirely unique, strategic move.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. The specific terms and relationship with Genezen, established after the July \u003cstrong\u003e2024\u003c\/strong\u003e sale, are not easily copied.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eExcellent. This was a deliberate, successful operational streamlining effort led by management, following a prior \u003cstrong\u003e20%\u003c\/strong\u003e headcount reduction in October.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Matt Kapusta to join Genezen Board of Directors.\u003c\/li\u003e\n\u003cli\u003eMajority of Lexington facility employees offered employment by Genezen.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. It’s a cost advantage, but manufacturing capacity is becoming more available across the industry.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 5: Diversified, Multi-Indication Pipeline\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Spreads risk beyond the single focus on Huntington's disease, including assets like AMT-260 for refractory MTLE, which showed promising early signals. The first participant in the AMT-260 trial showed a 92% reduction in seizure frequency over five months, with two seizures reported versus an average of seven seizures per month prior to treatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many smaller biotechs are single-asset focused; uniQure has several programs in development. The pipeline includes AMT-130 (HD), AMT-260 (MTLE), AMT-191 (Fabry disease), and AMT-162 (SOD1-ALS).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can pursue similar diseases, but uniQure has a head start in these specific programs. For example, the AMT-260 GenTLE Phase I\/IIa study is actively recruiting through 12 sites in the U.S..\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The company is actively managing and recruiting for multiple cohorts across different indications. Research and development expenses for the year ended December 31, 2024, were $143.8 million. Cash and cash equivalents were approximately $367.5 million as of December 31, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A broader pipeline offers more shots on goal for long-term value creation.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003ePhase\/Status\u003c\/th\u003e\n\u003cth\u003ePatient Cohorts\/Enrollment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-130\u003c\/td\u003e\n\u003ctd\u003eHuntington's Disease\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II (Pivotal)\u003c\/td\u003e\n\u003ctd\u003e29 treated patients with up to 36 months follow-up data available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-260\u003c\/td\u003e\n\u003ctd\u003eRefractory MTLE\u003c\/td\u003e\n\u003ctd\u003ePhase I\/IIa (GenTLE)\u003c\/td\u003e\n\u003ctd\u003eDesigned with two dose cohorts of six patients each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-191\u003c\/td\u003e\n\u003ctd\u003eFabry Disease\u003c\/td\u003e\n\u003ctd\u003ePhase I\/IIa\u003c\/td\u003e\n\u003ctd\u003eFour patients treated; second cohort of three patients completed enrollment; third cohort of three patients enrolling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-162\u003c\/td\u003e\n\u003ctd\u003eSOD1-ALS\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II (EPISOD1)\u003c\/td\u003e\n\u003ctd\u003eEnrollment paused after one patient in the second cohort experienced a dose-limiting toxicity; data being evaluated from five treated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 6: HEMGENIX® License Revenue Stream\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a source of non-dilutive revenue from an approved therapy (licensed to CSL), which helps offset R\u0026amp;D burn.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.5 million\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense Revenue Increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.4 million\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024 vs 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe revenue stream is directly tied to the commercial performance of the licensed asset, HEMGENIX®.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Having an approved, commercialized asset in the portfolio is rare for a company of this stage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe asset is an approved therapy for hemophilia B, allowing people to produce factor IX.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Sustained. Competitors cannot easily replicate an existing, approved product and its associated revenue stream.\u003c\/p\u003e\n\u003cp\u003eReplication difficulty is high due to the regulatory approval status already achieved by the licensee, CSL Behring.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The revenue stream is managed through the existing partnership structure.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has a development and commercial supply agreement with CSL Behring.\u003c\/li\u003e\n\u003cli\u003eCost of contract manufacturing revenues related to HEMGENIX® was \u003cstrong\u003enil\u003c\/strong\u003e for the three months ended September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCost of contract manufacturing revenues was \u003cstrong\u003e$0.8 million\u003c\/strong\u003e for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is a proven, revenue-generating asset that de-risks the overall business model.\u003c\/p\u003e\n\u003cp\u003eThe license revenue stream contributes to a strong liquidity position, supporting ongoing R\u0026amp;D efforts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and current investment securities totaled \u003cstrong\u003e$694.2 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThis cash position is expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 7: Prior FDA Regulatory Designations (BT\/RMAT)\n\u003c\/h2\u003e\n\u003cp\u003eThe regulatory designations for AMT-130 in Huntington's disease (HD) represent a historical achievement based on clinical evidence.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eStatus\/Data Point\u003c\/th\u003e\n\u003cth\u003eSupporting Detail\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSignaled potential for expedited review path\u003c\/td\u003e\n\u003ctd\u003eBreakthrough Therapy (BT) granted on \u003cstrong\u003eApril 17, 2025\u003c\/strong\u003e; RMAT granted in \u003cstrong\u003eMay 2024\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHard-won indication of high unmet need\u003c\/td\u003e\n\u003ctd\u003eBased on interim Phase I\/II data showing dose-dependent slowing of disease progression in up to \u003cstrong\u003e45\u003c\/strong\u003e treated patients as of April 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eSpecific FDA decision based on unique data\u003c\/td\u003e\n\u003ctd\u003eDesignations acknowledged preliminary evidence indicating potential to address unmet medical needs for HD.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eMixed effectiveness due to subsequent guidance shift\u003c\/td\u003e\n\u003ctd\u003ePre-BLA meeting on \u003cstrong\u003eOctober 29, 2025\u003c\/strong\u003e, resulted in FDA indicating Phase I\/II data are currently unlikely to support a BLA submission.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; utility diminished by recent feedback\u003c\/td\u003e\n\u003ctd\u003eDesignations remain, but BLA timing is now unclear following the late-2025 feedback, reversing prior guidance from November 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe designations secured for AMT-130 include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBreakthrough Therapy (BT) designation granted on \u003cstrong\u003eApril 17, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRegenerative Medicine Advanced Therapy (RMAT) designation granted in \u003cstrong\u003eMay 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOrphan Drug Designation.\u003c\/li\u003e\n\u003cli\u003eFast Track designation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe RMAT designation in \u003cstrong\u003eMay 2024\u003c\/strong\u003e was based on 24-month interim Phase I\/II data announced in December 2023, with subsequent interim data presented in July 2024 showing dose-dependent slowing of disease progression based on the cUHDRS metric.\u003c\/p\u003e\n\u003cp\u003eThe organization is now focused on urgent interactions with the FDA following the \u003cstrong\u003eOctober 29, 2025\u003c\/strong\u003e, pre-BLA meeting, with plans to request a follow-up meeting in the first quarter of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 8: Experienced Gene Therapy Leadership and Scientific Team\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Decades of experience in the complex field of gene therapy, including navigating the first commercial approval (HEMGENIX®), which is vital for future execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The sector has many smart people, but the specific, deep experience in commercializing gene therapy is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. It takes years to build a team with this specific, hard-won institutional knowledge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. Despite recent challenges, the team is actively managing trials and engaging with the FDA urgently, with a planned follow-up meeting in early \u003cstrong\u003e2026\u003c\/strong\u003e following late 2025 FDA feedback on AMT-130 data sufficiency.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Institutional memory and proven leadership are definitely hard to buy off the shelf.\u003c\/p\u003e\n\u003cp\u003eKey quantitative data points supporting the depth of this capability include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene Therapy Leadership Tenure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany history as a pioneer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO Drug Development Experience\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;20 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDr. Walid Abi-Saab's experience in global drug development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecules Advanced by CMO\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMolecules advanced through clinical development under Dr. Abi-Saab\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned AMT-130 BLA Submission\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected timeline following Q2 2025 alignment with FDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eH2 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on \u003cstrong\u003e$377.0 million\u003c\/strong\u003e cash position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe team's history includes achieving the world's first approved gene therapy and establishing the first commercially licensed gene therapy manufacturing facility. The company's Q2 2025 revenue was \u003cstrong\u003e$5.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003euniQure N.V. (QURE) - VRIO Analysis: Core Capability 9: Intellectual Property Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCore Capability 9: Intellectual Property Portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A broad set of patents covering the vector technology, manufacturing processes, and specific product compositions, which forms the legal barrier to entry for rivals.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Most successful biotechs have IP, but the breadth and depth in a niche like AAV delivery matter most.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Sustained. Patents provide legal protection that competitors cannot easily circumvent without infringing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The company lists IP protection as a key factor in its filings, suggesting active management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Strong IP is the bedrock of long-term value in pharma\/biotech.\u003c\/p\u003e\n\n\u003cp\u003eKey Intellectual Property Assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. Patent \u003cstrong\u003e10,174,321\u003c\/strong\u003e and EP Patent \u003cstrong\u003e3237618\u003c\/strong\u003e covering AMT-130 for Huntington's disease, including claims on RNA constructs targeting exon1 and embedding sequences into the miR451 scaffold.\u003c\/li\u003e\n\u003cli\u003eProprietary miQURE™ gene silencing technology platform.\u003c\/li\u003e\n\u003cli\u003eAcquired patent family covering hyperactive Factor IX variant (FIX-Padua, R338L mutation) for hemophilia B, including U.S. Patent \u003cstrong\u003e9,249,405\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrademark protection applied for marks miQURE and Super9.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eVRIO Assessment Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eGood\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: 13-Week Cash Flow Projection Incorporating Q3 Balance\u003c\/p\u003e\n\u003cp\u003eStarting Cash Balance (End of Q3 2025): \u003cstrong\u003e$694,200,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eEstimated Quarterly Net Loss (Q3 2024 proxy): \u003cstrong\u003e$44,400,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eEstimated Weekly Cash Outflow (Based on Q3 2024 Net Loss \/ 13 weeks): \u003cstrong\u003e$3,415,385\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek\u003c\/td\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003eEstimated Cash Inflows (e.g., Milestones\/Grants)\u003c\/td\u003e\n\u003ctd\u003eEstimated Cash Outflows (e.g., R\u0026amp;D\/SG\u0026amp;A Burn)\u003c\/td\u003e\n\u003ctd\u003eNet Cash Flow\u003c\/td\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$694,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$690,784,615\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$690,784,615\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$687,369,230\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$687,369,230\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$683,953,845\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$683,953,845\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$680,538,460\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$680,538,460\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$677,123,075\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$677,123,075\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$673,707,690\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$673,707,690\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$670,292,305\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$670,292,305\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$666,876,920\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$666,876,920\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$663,461,535\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$663,461,535\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$660,046,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$660,046,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$656,630,765\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$656,630,765\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$653,215,380\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$653,215,380\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e($3,415,385)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$649,800,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516238356629,"sku":"qure-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/qure-vrio-analysis.png?v=1740226696","url":"https:\/\/dcf-model.com\/products\/qure-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}